<<<The street has had a hard time understanding LGND for quite some time. Consequently, its price has always been cheap. LGND has a couple of core technologies that target huge markets. They are under funded, so some of the larger indications have been partnered out. Big pharmas have a better understanding of LGND's technology, so they have created many alliances (PFE, GLX, AGN, ABT, AHP, SBH, Sankyo, LLY and WLA through AGN). The street isn't even close to understanding the implications of the polypeptide hormone mimics >>>
You said it, Henry! The street isn't even close to understanding. The question is if and when they will ever understand it. The answer is no! No, never will the street *understand* this technology. That's the problem. They only care if drugs get approved for big markets that will make them money. It's that simple. Only a few people will put the time into "understanding." Most people first look at the numbers on the quarterly reports, and if that looks ok, which they don't right now, then they might explore the company a little further. In the end, people want to know if it's going to make money. Your dreaming or living in your own scientific world if you think enough people are going to "understand" anything about Ligand. Will LGND's technology make enough money in the next three years to dramatically slow the offering of new stocks? Why don't you answer that question, because it's a hell of a lot more important than anyone understanding anything about Ligand's technology! "Understanding" isn't the key and won't happen. |
